期刊文献+

质子泵抑制剂对十二指肠球部溃疡患者血清胃泌素浓度的影响研究 被引量:1

下载PDF
导出
摘要 选择2014年10月~2016年10月我院就诊胃镜诊断的十二指肠球部溃疡患者120例,按随机数字表随机分成治疗组60例,采用质子泵抑制剂雷贝拉唑阶梯停药方法治疗,对照组60例采用常规雷贝拉唑治疗。比较两组患者治疗前与治疗后9周、6个月、12个月、复发病例血清胃泌素水平的变化,1年后复发病例数,以及治疗的临床效果。两组患者血清胃泌素水平与复发情况比较,治疗后9周、6个月、1年患者血清胃泌素水平有统计学差异(P<0.05),而两组复发患者血清胃泌素水平没有统计学差异(P>0.05),1年后疾病复发率治疗组12.07%,对照组36.84%有显著的统计学差异(P<0.05)。两组临床疗效比较有统计学差异,治疗组有效率94.82%,对照组78.95%。质子泵抑制剂雷贝拉唑阶梯停药方法治疗十二指肠球部溃疡,使胃泌素分泌水平逐步降低,从而减少了十二指肠球部溃疡的复发率,是值得在临床上推广的一种质子泵抑制剂治疗十二指肠球部溃疡的新方法。
出处 《现代诊断与治疗》 CAS 2017年第20期3840-3842,共3页 Modern Diagnosis and Treatment
  • 相关文献

参考文献1

二级参考文献17

  • 1DELCHIER J G, COHEN G, HUMPHRIES T J. Rabeprazole, 20 mg once daily or 10 mg twice daily, in the healing of erosive gastrooesphageal reflux disease[J]. Scand J Gastroenterol, 2000, 35(12): 1 245-1 250.
  • 2MIWA H, YAMADA T, SATO K. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole[J]. Dig Dis Sci, 2000, 45(1): 77-82.
  • 3TSUTSUI N, TANEIKE I, OHARA T, et al. A novel action of the proton pump inhibitor Rabeprazole and its thioether derinative against the motility of Helicobacter pylory[J]. Antimicrob Agents Chemother, 2000, 44(11): 3 069-3 073.
  • 4HIZAWA K, NAKAHARA J, YANO Y, et al. Effect of amixicillin, clarithromycin and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection[J]. J Clin Gastroenterol, 2000, 31(4): 338-339.
  • 5NISHINA K, MIKAWA K, TAKAO I, et al. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery[J]. Anesth Analg, 2000, 90(3): 717-721.
  • 6DEKKERS C P, BEKER J A, THJODLEIFESSON B, et al. Double-blind comparison [correction of double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 1999, 13(1): 49-57.
  • 7KEANE W F, SWAN S K, GRIMES I, et al. Rabeprazole: pharmacokinetics and tolerability in patients with stable,end-stage renal failure[J]. J Clin Pharmacol, 1999, 39(9): 927-933.
  • 8DAMMANN H G,BURHARDT F, WOLF N. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers[J]. Aliment Pharmacol Ther, 1999, 13(9): 1 195-1 203.
  • 9HONGO M, KIMPARA T, MORIYAMA S, et al. Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers[J]. Tohoku J Exp Med, 1998, 186(1): 43-50.
  • 10LANGTRY H D, MARKHAM A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders[J]. Drugs, 1999, 58(4): 725-742.

共引文献16

同被引文献18

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部